Navigation Links
Agendia BV Appoints Clinical and Scientific Advisory Board
Date:10/29/2007

Six Eminent Cancer Researchers Advise Agendia

AMSTERDAM, October 29 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics has appointed six members to its Clinical and Scientific Advisory Board. The newly established Clinical and Scientific Advisory Board is comprised of internationally-recognized scientists with research and clinical expertise. The advisors review early research programs and provide critical evaluations from academic and clinical perspectives.

Agendia welcomes:

Piet Borst (chair), M.D., PhD, CBE, For Mem RS, Staff Member and Emeritus Director of the Netherlands Cancer Institute and Professor of Clinical Biochemistry, Amsterdam, The Netherlands

Jose Baselga M.D., Professor of Medicine and Chairman of the medical oncology service, Vall d'Hebron University Hospital, Barcelona, Spain

Matt van de Rijn, M.D., Ph.D, Professor of Pathology, Stanford University, School of Medicine, Stanford, CA, USA

David Kerr M.D., Professor of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford, UK

C. Kent Osborne, M.D., Professor of Medicine and, Director, Breast Center Baylor College of Medicine, Houston, Texas, USA, Director, Dan L. Duncan Cancer Center at Baylor College of Medicine

Joe W. Gray, Ph.D., Director, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA and Professor UCSF Comprehensive Cancer Center.

"We are very pleased that this outstanding group of scientist-clinicians has agreed to join Agendia's clinical and scientific advisory board", says Prof. dr. Rene Bernards, Chief Scientific Officer at Agendia. "Their insights into the clinical needs of cancer patients will help us to tailor our product portfolio to best serve patients and their doctors to optimize the treatment for each individual patient."

"The addition of these six distinguished scientists and clinicians will enable us to further strengthen strategies in cancer and other diseases" said Dr. Bernhard Sixt, Chief Executive Officer at Agendia.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to obtain FDA approval for it's breast cancer test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

* CupPrint(R) is based on a license to the TUO database of AviaraDx


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
Breaking Biology News(10 mins):